These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1911 related articles for article (PubMed ID: 30979735)
21. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312 [TBL] [Abstract][Full Text] [Related]
22. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640 [No Abstract] [Full Text] [Related]
23. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441 [TBL] [Abstract][Full Text] [Related]
24. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221 [TBL] [Abstract][Full Text] [Related]
25. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063 [TBL] [Abstract][Full Text] [Related]
26. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886 [TBL] [Abstract][Full Text] [Related]
27. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334 [TBL] [Abstract][Full Text] [Related]
28. Fully human antibody V Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386 [TBL] [Abstract][Full Text] [Related]
29. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains. Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637 [TBL] [Abstract][Full Text] [Related]
30. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector. Lee HJ; Hwang SJ; Jeong EH; Chang MH J Microbiol; 2024 Jul; 62(7):555-568. PubMed ID: 38700775 [TBL] [Abstract][Full Text] [Related]
31. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281 [TBL] [Abstract][Full Text] [Related]
32. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P Front Immunol; 2019; 10():1149. PubMed ID: 31178870 [TBL] [Abstract][Full Text] [Related]
33. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Ma Q; Gomes EM; Lo AS; Junghans RP Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378 [TBL] [Abstract][Full Text] [Related]
34. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708 [TBL] [Abstract][Full Text] [Related]
35. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo. Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967 [TBL] [Abstract][Full Text] [Related]
36. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
37. CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Velasquez MP; Szoor A; Vaidya A; Thakkar A; Nguyen P; Wu MF; Liu H; Gottschalk S Cancer Immunol Res; 2017 Oct; 5(10):860-870. PubMed ID: 28821531 [TBL] [Abstract][Full Text] [Related]
38. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X Front Immunol; 2020; 11():539654. PubMed ID: 33281809 [TBL] [Abstract][Full Text] [Related]